CELLULAR RAS ACTIVITY IS REQUIRED FOR PASSAGE THROUGH MULTIPLE POINTSOF THE G(0) G(1) PHASE IN BALB/C 3T3 CELLS/

Citation
S. Dobrowolski et al., CELLULAR RAS ACTIVITY IS REQUIRED FOR PASSAGE THROUGH MULTIPLE POINTSOF THE G(0) G(1) PHASE IN BALB/C 3T3 CELLS/, Molecular and cellular biology, 14(8), 1994, pp. 5441-5449
Citations number
44
Categorie Soggetti
Biology
ISSN journal
02707306
Volume
14
Issue
8
Year of publication
1994
Pages
5441 - 5449
Database
ISI
SICI code
0270-7306(1994)14:8<5441:CRAIRF>2.0.ZU;2-Z
Abstract
Microinjection experiments demonstrated a requirement for cellular ras activity late in G(1). In this study, we used two separate methods to identify an additional requirement for cellular ras activity early in the G(0)/G(1), phase of the cell cycle. Quiescent BALB/c cells were i njected with anti-ras antibody prior to stimulation with serum. The ce lls would therefore be inhibited in progression through the cell cycle at the earliest point requiring ras function. Alternatively, cells we re inhibited in late G(1) as in previous studies by injecting anti-ras several hours after serum addition to quiescent cells. The injected c ultures were then treated with chemical cell cycle inhibitors known to function in mid-G(1). Cells injected with anti-ras prior to serum sti mulation were retained at a point of ras requirement prior to the exec ution point of the chemical inhibitor, while cells injected 3 to 5 h a fter serum stimulation were retained at a point of ras requirement dow nstream of the execution point of the chemical inhibitor. To confirm t hese results, quiescent BALB/c cells were injected with anti-ras antib ody prior to or several hours following serum addition. In this case, however, second injections of oncogenic ras or adenoviral E1A protein were performed to overcome the inhibitory effects of the anti-ras anti body. Cells injected prior to serum addition were clearly inhibited at an early point of Ras requirement since they required 5 or 6 h longer to enter S phase than cells injected with anti-ras antibody after ser um addition.